《Prostate Cancer And Prostatic Diseases》雜志的最新年發(fā)文量為95篇。
這表明該刊在每年都會(huì)精選并發(fā)表一定數(shù)量的高質(zhì)量文章，以保持其在泌尿?qū)W與腎臟學(xué)領(lǐng)域的學(xué)術(shù)影響力。
該刊聚焦于醫(yī)學(xué)-泌尿?qū)W與腎臟學(xué)領(lǐng)域的前沿研究，致力于推動(dòng)該領(lǐng)域新技術(shù)和新知識(shí)的傳播與應(yīng)用。同時(shí)它積極鼓勵(lì)研究人員詳細(xì)發(fā)表其高質(zhì)量的實(shí)驗(yàn)研究和理論成果。
該刊的平均審稿周期約為 較慢,6-12周 。
Prostate Cancer And Prostatic Diseases 雜志發(fā)文統(tǒng)計(jì)
文章名稱引用次數(shù)
- Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations29
- The microbiome in prostate inflammation and prostate cancer21
- Ga-68-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology19
- Compositional differences in gastrointestinal microbiota in prostate cancer patients treated with androgen axis-targeted therapies18
- The use of PET/CT in prostate cancer17
- Prevalence of DNA repair gene mutations in localized prostate cancer according to clinical and pathologic features: association of Gleason score and tumor stage17
- Prostatic Urethral Lift (PUL) for obstructive median lobes: 12 month results of the MedLift Study15
- Prostate-specific antigen (PSA) density in the diagnostic algorithm of prostate cancer15
- Processed and raw tomato consumption and risk of prostate cancer: a systematic review and dose-response meta-analysis15
- p53 status in the primary tumor predicts efficacy of subsequent abiraterone and enzalutamide in castration-resistant prostate cancer14
國(guó)家/地區(qū)發(fā)文量
- USA179
- Italy40
- Canada35
- GERMANY (FED REP GER)26
- England25
- CHINA MAINLAND24
- Australia18
- Netherlands14
- Sweden14
- Austria12
